Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.
Related contacts
Bill Roegge
Partner, New York
Kenneth Krisko
Partner, Reston
Simon Amies
Partner, London
Rita Sobral
Special Counsel, London
Stephanie Parker Palmer
Special Counsel, Reston
Michael Bergmann
Partner, Washington, DC
Brandon W. Fenn
Partner, New York
Eileen Marshall
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Stella Sarma
Partner, Brussels
Ryan Vann
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew Choy
Associate, New York
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Edward (Teddy) Nimetz
Associate, New York
Alexandra Paterson
Associate, London
Joseph Perry
Associate, Reston